Sort   by:  
 Page size 
ProteomicsDevelopment and crystal structures of a more potent second-generation dual degrader of BCL-2 and BCL-xL
Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved potency and reduced toxicity compared to previous small molec...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-02-21 | MSV000094144 | MassIVE
ProteomicsDevelopment and crystal structures of a more potent second-generation dual degrader of BCL-2 and BCL-xL
Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved potency and reduced toxicity compared to previous small molec...
ORGANISM(S): Homo sapiens (Human) 
2024-03-12 | PXD049976 | Pride
Protac Crystal structure Ubiquitin Ternary complex Degrader E3 ligase Bcl-xl/bcl-2 
TranscriptomicsTranscription profiling of human SCLC cell line set 2
RNA expression analysis was performed to compare patterns to sensitivity to BCL2 inhibitors (ABT-263). Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL and Mcl-1) is commonly associated with tumor maintenance, progression and chemoresistance. We previously reported the discover...
ORGANISM(S): Homo sapiens 
2008-06-19 | E-GEOD-10841 | biostudies-arrayexpress
GenomicsEpigenetic Targeting of Mcl-1 is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
Epigenetic Targeting of Mcl-1 is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
PRJNA634319 | ENA
GenomicsDual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine
PRJNA1373333 | ENA
TranscriptomicsIGR_SCLC_CELL_LINES_GE_YL
Radiotherapy has a critical role in the treatment of small cell lung cancer (SCLC). Effectiveness of radiation in SCLC remains limited as resistance results from defects in apoptosis. In the current study, we investigated whether using a Bcl-2/Bcl-XL inhibitor S44563 can enhance radiosensitivity of ...
ORGANISM(S): Homo sapiens 
2013-02-01 | E-MTAB-966 | biostudies-arrayexpress
GenomicsEpigenetic Targeting of Mcl-1 is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
Glioblastomas harbor a super-enhancer at the MCL1 locus, which translates to increased MCL1 levels as compared to normal brain tissue. While suppression of Mcl-1 alone did not yield in significant apoptosis induction, combined inhibition of Bcl-xL/Bcl-2 along with Mcl-1 led to strong cell killing an...
ORGANISM(S): Homo sapiens 
2020-05-22 | GSE150986 | GEO
GenomicsDual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine
Background: The BCL-2 inhibitor venetoclax in combination with a hypomethylating agent is effective against most acute myeloid leukemia (AML) subtypes, but less so against other high-risk myeloid neoplasms. One resistance mechanism to BCL-2 inhibition is increased dependence on alternate BH3-only an...
ORGANISM(S): Homo sapiens 
2026-04-20 | GSE312447 | GEO
UnknownTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
Not available
S-EPMC3890263 | biostudies-literature
UnknownStructure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
Not available
S-EPMC3417242 | biostudies-literature
Sort   by:  
 Page size